Discussion about this post

User's avatar
The AI Architect's avatar

The Revolution Medicines update caught my attention. Given MRK's oncology focus, it seemed like a natural fit strategically. Buyout talks falling through often signals price disagremetn rather than strategic misalignment. Wonder if this opens up room for alternative suitors or if Revolution pivots to standalone growth.

No posts

Ready for more?